Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

76 to 100 of 418 results

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

13-03-2014

UK pharma giant GlaxoSmithKline says that a pivotal Phase III study of mepolizumab, an investigational…

GlaxoSmithKlinemepolizumabPharmaceuticalResearchRespiratory and Pulmonary

GSK increases stake in Indian Pharma subsidiary to 75%

GSK increases stake in Indian Pharma subsidiary to 75%

10-03-2014

UK pharma giant GlaxoSmithKline says that, following the voluntary open offer undertaken by its Indian…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

ISIS Pharma earns $1 million from GSK for advancing ISIS-TTRRx

03-03-2014

USA-based Isis Pharmaceuticals has earned a $1 million milestone payment from UK pharma giant GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTRRxPharmaceuticalRare diseasesResearch

GSK files for US approval for Promacta for severe aplastic anemia

GSK files for US approval for Promacta for severe aplastic anemia

02-03-2014

UK pharma giant GlaxoSmithKline has submitted a supplemental New Drug Application to the US Food and…

GlaxoSmithKlineLigand PharmaceuticalsNorth AmericaOncologyPharmaceuticalPromactaRare diseasesRegulationUSA

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

GSK receives positive CHMP opinion for COPD drug Incruse

GSK receives positive CHMP opinion for COPD drug Incruse

21-02-2014

GlaxoSmithKline has announced that the European Medicines Agency’s Committee for Medicinal Products…

GlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUKumeclidinium

GSK and Theravance’s Anoro gets positive EMA panel backing for COPD

GSK and Theravance’s Anoro gets positive EMA panel backing for COPD

21-02-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Anoro ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance Biopharma

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Cost is preventing boys receiving anti-cancer vaccine for HPV

Cost is preventing boys receiving anti-cancer vaccine for HPV

13-02-2014

While national health systems have been pushing to increase the human papillomavirus (HPV) vaccine uptake…

CervarixEuropeGardasilGlaxoSmithKlineHealthcareMerck & CoPharmaceuticalUSAVaccines

GlaxoSmithKline sales beat forecasts, as 4th-qtr net income nearly triples

GlaxoSmithKline sales beat forecasts, as 4th-qtr net income nearly triples

05-02-2014

UK pharma giant GlaxoSmithKline’s financial report for fourth-quarter and full-year 2013 pleased investors,…

FinancialGlaxoSmithKlinePharmaceutical

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

03-02-2014

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for UK pharma…

GlaxoSmithKlinePharmaceuticalPromactaRare diseasesRegulationRevolade

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

27-01-2014

UK pharma major GlaxoSmithKline announced that its Phase III study of the combination of Tafinlar (dabrafenib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalResearchTafinlarUK

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

24-01-2014

Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal…

DiabetesEperzanGlaxoSmithKlinePharmaceuticalRegulation

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients

20-01-2014

A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

13-01-2014

Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

09-01-2014

GlaxoSmithKline (LSE: GSK) says that the US Food and Drug Administration has approved Mekinist (trametinib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlarUKUSA

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

Blend Therapeutics names former GSK VP Richard Wooster as chief scientific officer

Blend Therapeutics names former GSK VP Richard Wooster as chief scientific officer

07-01-2014

US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard…

Blend TherapeuticsBoardroomGlaxoSmithKlinePharmaceuticalUSA

76 to 100 of 418 results

Back to top